Document is current
Any future updates will be listed below
-
Authors
Yiangou, Andreas
Do, Thien Phu
Grech, Olivia
Mugo, Caroline W.
Thomas, Chloe N.
Gew, Jessie
Lange, Maria G.
Gee, Megan
Mollan, Susan P.
Hill, Lisa J.
Lucas, Samuel J. E.
Ashina, Messoud
Sinclair, Alexandra J.
- License Information
-
More Information
Article History
Received: 18 March 2026
Accepted: 3 May 2026
First Online: 13 June 2026
Declarations
:
: This study (IIH Provoke: ISRCTN13251508, registered: 24/10/2022) was approved by the National Research Ethics Committee of North East - Newcastle & North Tyneside 1 (22/NE/0081). All participants provided written informed consent to participate in the study, in accordance with the Declaration of Helsinki.
: AY reports speaker fees from Teva UK. SPM reports consultancy fees (Invex Therapeutics); advisory board fees (Ocular Therapeutix, Dompé); Speaker fees (Teva, AbbVie); Travel (Abbvie and European Alliance of Associations for Rheumatology); Receipt of equipment (Heidelberg Engineering). SPM is a section editor at Eye Journal, Eye Open and Journal of Neuro-ophthalmology. OG reports consulting fees from Invex Therapeutics unrelated to this research. MA reports receiving personal fees from AbbVie, Astra Zeneca, Eli Lilly, GlaxoSmithKline, Incyte, Lundbeck, Novartis, Pfizer and Teva Pharmaceuticals outside of the submitted work. MA reports serving as associate editor of The Journal of Headache and Pain and associate editor of Brain. AJS reports she has consulted for Novartis, AbbVie, Vertex and Orion Pharma and speaker fees from Teva Uk and Novartis on unrelated topics.
